Dynamic Technology Lab Private Ltd Makes New Investment in Bio-Techne Co. (NASDAQ:TECH)

Dynamic Technology Lab Private Ltd bought a new position in Bio-Techne Co. (NASDAQ:TECH) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,202 shares of the biotechnology company’s stock, valued at approximately $879,000.

A number of other institutional investors have also modified their holdings of TECH. UMB Bank n.a. raised its stake in Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 168 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Bio-Techne by 60.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 253 shares in the last quarter. Versant Capital Management Inc lifted its stake in Bio-Techne by 35.0% during the fourth quarter. Versant Capital Management Inc now owns 763 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 198 shares during the last quarter. Huntington National Bank lifted its stake in Bio-Techne by 42.6% during the fourth quarter. Huntington National Bank now owns 1,078 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 322 shares during the last quarter. Finally, Kiely Wealth Advisory Group Inc. increased its stake in Bio-Techne by 1,355.6% during the fourth quarter. Kiely Wealth Advisory Group Inc. now owns 1,048 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 976 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Price Performance

Shares of TECH opened at $51.72 on Monday. Bio-Techne Co. has a one year low of $49.89 and a one year high of $85.57. The stock’s fifty day moving average is $64.44 and its 200-day moving average is $70.78. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94. The firm has a market capitalization of $8.18 billion, a price-to-earnings ratio of 52.24, a price-to-earnings-growth ratio of 2.88 and a beta of 1.30.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. Equities analysts anticipate that Bio-Techne Co. will post 1.67 EPS for the current year.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Monday, February 17th were given a $0.08 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a yield of 0.62%. Bio-Techne’s dividend payout ratio (DPR) is 32.32%.

Wall Street Analysts Forecast Growth

TECH has been the topic of a number of recent research reports. Baird R W downgraded shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Royal Bank of Canada lifted their target price on Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, February 6th. Scotiabank increased their price target on Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 6th. Evercore ISI assumed coverage on Bio-Techne in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Friday. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $81.25.

Insider Buying and Selling at Bio-Techne

In other news, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the completion of the sale, the chief executive officer now owns 39,004 shares in the company, valued at $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Amy E. Herr sold 1,860 shares of Bio-Techne stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $65.96, for a total value of $122,685.60. Following the transaction, the director now directly owns 1,976 shares in the company, valued at approximately $130,336.96. The trade was a 48.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by corporate insiders.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.